MARKHAM, Ontario, Aug. 12, 2024 (GLOBE NEWSWIRE) — Extendicare Inc. (“Extendicare” or the “Company”) (TSX: EXE) today reported results for the three and six months ended June 30, 2024. Second Quarter 2024 Highlights Adjusted EBITDA(1) excluding out-of-period items improved by $19.7 million to $34.5 million, largely driven by rate increases in long-term care (“LTC”) and […]
Category Archives: Pr Newswire
Pr Newswire
Orchestra BioMed Reports Second Quarter 2024 Financial Results and Provides a Business Update
13
Aug
Aug
NEW HOPE, Pa., Aug. 12, 2024 (GLOBE NEWSWIRE) — Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today reported its second quarter 2024 financial results and provided a business update. “Our work in hypertension and coronary artery disease aligns […]
13
Aug
Aug
FORT WORTH, TX, Aug. 12, 2024 (GLOBE NEWSWIRE) — Sanara MedTech Inc. Based in Fort Worth, Texas, Sanara MedTech Inc. (“Sanara,” the “Company,” “we,” “our” or “us”) (NASDAQ: SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, chronic wound and skincare […]
Adalimumab-aaty was first approved by the Food and Drug Administration on May 23, 2023 and became commercially available among key distributors across the U.S. on July 2, 2023 Adalimumab-aaty’s inclusion creates greater accessibility to treatments for Americans with inflammatory conditions JERSEY CITY, N.J., Aug. 13, 2024 /PRNewswire/ — Celltrion USA, Inc., (Celltrion USA) today announced […]
Toss Securities logs exceptional financial performance, achieving full-year target in just six months Strong performance in U.S. securities trading was instrumental in driving growth Building on quarterly profit in Q1, Toss Securities’ strong Q2 results highlight consistent profitability SEOUL, South Korea, Aug. 13, 2024 /PRNewswire/ — Toss Securities has reported a strong performance in the […]
LETHAM, Scotland, Aug. 13, 2024 /PRNewswire/ — MDJM LTD (Nasdaq: MDJH) (the “Company” or “MDJM”), an integrated global culture-driven asset management company, announced today the appointment of Dr. Pei-Kai Cheng to the Expert Committee of its wholly owned subsidiary, MD Local Global Limited, a United Kingdom Company. Dr. Cheng’s involvement marks a significant enhancement to […]
OXFORD, England, Aug. 13, 2024 /PRNewswire/ — Unipart, the supply chain solutions and performance improvement technologies partner, has announced the acquisition of the former Schaeffler Rail Bearing reconditioning business in Auburn, New South Wales. Mark Carling, Unipart Rail Australia & Asia Pacific Managing Director The acquisition was completed on 12 August 2024, transferring the business […]
DUBAI, UAE, Aug. 13, 2024 /PRNewswire/ — Yalla Group Limited (“Yalla” or the “Company”) (NYSE: YALA), the largest Middle East and North Africa (MENA)-based online social networking and gaming company, today announced its unaudited financial results for the second quarter ended June 30, 2024. Second Quarter 2024 Financial and Operating Highlights Revenues were US$81.2 million in the second […]
Pr Newswire
Taysha Gene Therapies Reports Second Quarter 2024 Financial Results and Provides Corporate Update
12
Aug
Aug
Presented cohort one (low dose) data from both trials of TSHA-102 at 2024 IRSF Rett Syndrome Scientific Meeting that demonstrated durable improvements across consistent clinical domains and an encouraging safety profile in adult (up to 52 weeks) and pediatric (up to 22 weeks) patients TSHA-102 was generally well tolerated with no SAEs or DLTs as […]
Pr Newswire
MBX Biosciences Doses First Patient in Phase 2 Avail™ Trial of MBX 2109 for the Treatment of Hypoparathyroidism
12
Aug
Aug
Topline results expected in Q3 2025 CARMEL, Ind., Aug. 12, 2024 (GLOBE NEWSWIRE) — MBX Biosciences, Inc., a clinical stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced that it has dosed the first patient in its Phase 2 Avail™ […]